AMGN compared with APGE: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

APGEApogee Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

APGEApogee Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

Q3 FY25±3.7%▲+7.81%×2.11

APGE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±0.6%▼−0.14%×0.17

Q1 FY26±7.8%▲+1.89%×0.24

= impliedAMGN realized, solidAPGE realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

Q3 FY25

±8.7%

▲+3.77%

×0.44

Aug 11 '25±7.7%▼−2.09%×0.27

AMGNAmgen Inc

465.45· pre 463.50· delayed

Mkt cap$251.6BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

APGEApogee Therapeutics, Inc.

135.07· pre 135.10· delayed

Pre-marketNov 3 '26delayed

Mkt cap$10.2BRevenue—Revenue—

Compare

Pre-marketNov 3 '26delayed

AMGNAmgen Inc

APGEApogee Therapeutics, Inc.

465.45pre 463.50delayed

Price

135.07pre 135.10delayed

$251.6B

Mkt cap

$10.2B

Q2 FY26$10.1B

Revenue

—

FY25$36.8B

Revenue

—

AMGN465.45vsAPGE135.07Pre-marketNov 3 '26delayed